Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25776543 | 0.88 | KDM4E (0.53) | SMN1; SMN2KDM4ENPSR1CYP4F2CYP4A11 | |
| SCHEMBL8490992 | 0.88 | TDP1 (0.70) | SMN1; SMN2KDM4ENPSR1GAATDP1 | |
| SCHEMBL7723906 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2TDP1ALDH1A1MAPTMEN1 | |
| SCHEMBL550516 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2GAATDP1ALDH1A1MAPT | |
| SCHEMBL9587613 | 0.85 | KDM4E (0.52) | SMN1; SMN2KDM4ENPSR1GAATDP1 | |
| SCHEMBL5539008 | 0.84 | KDM4E (0.57) | SMN1; SMN2KDM4ENPSR1GAATDP1 | |
| SCHEMBL3299225 | 0.84 | CA12 (0.62) | SMN1; SMN2NPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL14114749 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4ENPSR1GAAALDH1A1 | |
| SCHEMBL7665374 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2NPSR1TDP1ALDH1A1LMNA | |
| SCHEMBL2616927 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2TDP1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524129-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYL ACETONITRILE COMPOUND AND USE THEREOF | Maxunitech Inc. (CN) | 2025-03-19 | — | — | EP | disclosed |
| US-20250059132-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF | MAXUNITECH INC (CN) | 2025-02-20 | — | — | US | disclosed |
| CN-117069614-A | Preparation method and application of 2-substituted aryl acetonitrile compound | 合力科技股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023216063-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYL ACETONITRILE COMPOUND AND USE THEREOF | 合力科技股份有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-10294218-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | VIROSTATICS SRL (IT) | 2019-05-21 | — | — | US | disclosed |
| CN-104822380-B | The novel disubstituted aminopyridine derivative of 4,6- | 维罗斯塔蒂克斯公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-2887943-B1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES | VIROSTATICS SRL (IT) | 2017-12-06 | — | — | EP | disclosed |
| EP-2887943-B1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES | VIROSTATICS SRL (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | VIROSTATICS SRL (IT) | 2017-07-20 | — | — | US | disclosed |
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | VIROSTATICS SRL (IT) | 2017-07-20 | — | — | US | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-6620827-B2 | Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents | TULARIK INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030088103-A1 | PPARgamma modulators | TULARIK INC. (US) | 2003-05-08 | — | — | US | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1053227-A1 | PPAR-GAMMA MODULATORS | TULARIK, INC. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038845-A1 | PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| US-5118680-A | COMBATING ENDOPARASITES WITH 3-HYDROXYBENZOTHIOPHENES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294218-B2 | 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity | DUT, UMPS, DPYD | SMN1; SMN2 4007/4885KDM4E 259/4885NPSR1 4591/4885 |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SMN1; SMN2 1268/4885KDM4E 2701/4885NPSR1 195/4885 |
| US-20030088103-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | SMN1; SMN2 3973/4885KDM4E 4173/4885NPSR1 2934/4885 |
| US-20250059132-A1 | METHOD FOR PREPARING 2-SUBSTITUTED ARYLACETONITRILE COMPOUND AND APPLICATION THEREOF | CYP1B1, CYP1A2, CYP2C9 | SMN1; SMN2 2364/4885KDM4E 1649/4885NPSR1 3465/4885 |
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | SMN1; SMN2 3973/4885KDM4E 4173/4885NPSR1 2934/4885 |
| US-20170204084-A1 | NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVE ANTI-HIV ACTIVITY | UMPS, DPYD, DUT | SMN1; SMN2 4318/4885KDM4E 272/4885NPSR1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.